BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer OncLive Initially, research into the mTOR inhibitor everolimus was undertaken in the neoadjuvant setting, looking for a potential biomarker, explains Rugo. In this trial, a great deal of information was uncovered about treatment with everolimus, including the ... |
